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Abstract
Purpose A phase III trial assessed the efficacy of
palonosetron plus dexamethasone given once in prevent-
ing acute and delayed chemotherapy-induced nausea and
vomiting (CINV) following a broad range of moderately
emetogenic chemotherapy (MEC) regimens.
Methods This multicentre, randomized, open-label, non-
inferiority trial evaluated two different treatment groups.
One group received palonosetron (0.25 mg intravenously)
and dexamethasone (8 mg intravenously) before chemo-
therapy, while the other was administered the same
r e g i m e no nd a y1f o l l o w e db yd e x a m e t h a s o n e8m go r a l l y
on days 2 and 3. The primary endpoint was complete
response (CR; defined as no emetic episodes and no
rescue medication) during the overall phase (days 1–5
after chemotherapy initiation). The non-inferiority margin
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DOI 10.1007/s00520-010-0941-7was predefined as a 15% difference between groups in the
primary endpoint.
Results Of 332 chemotherapy-naïve patients included in the
intention-to-treat analysis, 65.1% were female, and 35.2%
received anthracycline plus cyclophosphamide (AC)-based
regimens. Overall CR rates were 67.5% for those admin-
istered dexamethasone only on day 1 (n=166), and 71.1%
for those also administered dexamethasone on days 2 and 3
(n=166; difference −3.6% (95% confidence interval, −13.5
to 6.3)). CR rates were not significantly different between
groups during the acute (0–24 h post-chemotherapy; 88.6%
versus 84.3%; P=0.262) and delayed phases (days 2–5;
68.7% versus 77.7%; P=0.116).
Conclusions Palonosetron plus single-dose dexamethasone
administered before common MEC regimens provide pro-
tection against acute and delayed CINV which is non-
inferior to that of palonosetron plus dexamethasone for
3 days. However, the major benefit of the single-day regimen
occurs in patients receiving non-AC MEC regimens.
Keywords Palonosetron.Serotonin antagonists.
Dexamethasone.Moderately emetogenic chemotherapy.
Nausea.Vomiting
Introduction
Chemotherapy-induced nausea and vomiting (CINV) can
severely impact performance status and quality of life [1].
CINV has been traditionally categorized as acute or
delayed: acute CINV is that occurring within 24 h after
initiation of chemotherapy, whereas delayed emesis is that
occurring between days 2 and 5 [2]. The risk of CINV
depends on several factors, although the emetogenic
potential of the chemotherapeutic agent is the most
predictive factor [3]. Intravenously administered cytotoxic
agents were initially assigned to five levels of emetoge-
nicity that was subsequently divided into four emetic risk
categories (high, moderate, low, and minimal) [4, 5]. A
critical factor in guiding anti-emetic treatment is the ability
of chemotherapy to induce a substantial risk of delayed
emesis. There is limited knowledge of the potential for
delayed emesis of many moderately emetogenic agents, but
recent guidelines support the use of a serotonin (5-HT3)-
receptor antagonist plus dexamethasone before moderately
emetogenic chemotherapy (MEC), with either agent given
alone on days 2 and 3 [6]. A meta-analysis of results from 32
trials that included 5,613 patients who received highly
emetogenic chemotherapy or MEC indicated that dexameth-
asone is superior to placebo or no treatment for complete
protection against both acute and delayed CINV [7]. Most
clinical trials also found that the addition of dexamethasone is
more effective than a 5-HT3-receptor antagonist alone for
control of acute and delayed emesis [2]. However, dexameth-
asone for prophylaxis of delayed emesis after MEC induces
moderate-to-severe adverse effects that may have substantial
impact on the quality of life [8]. In addition, the first-
generation 5-HT3-receptor antagonists have only modest
efficacy in prevention of delayed emesis induced by MEC [9].
12]. Pooled analysis of these trials showed that palonosetron
also induces a statistically significant improvement in the CR
rate during the acute phase compared with pooled data from
patients who received ondansetron or dolasetron (72% versus
61%, respectively) [13]. Significantly more patients receiving
palonosetron achieved complete protection from delayed
CINV compared with those who received either ondansetron
or dolasetron (64% versus 47%, respectively). It is well
known that the addition of dexamethasone to a 5-HT3-
receptor antagonist improves the anti-emetic efficacy during
the acute phase, control of which is the strongest prognostic
factor for successful prevention of delayed CINV [2, 14]. In a
recent open-label, phase II study evaluating the combination
of palonosetron and dexamethasone (8 mg) administered
intravenously on day 1 in patients receiving MEC, CR was
seen in 84% of patients during the acute phase [15].
Based on this data, palonosetron plus a single dose of
dexamethasone administered before chemotherapy might
provide a more convenient regimen for the prevention of
acute and delayed CINV following MEC regimens.
Accordingly, the present phase III trial was designed to
test the hypothesis that the efficacy of a single-day two-
drug regimen against CINV is non-inferior to that of the
same regimen with additional dexamethasone doses on
days 2 and 3 after chemotherapy initiation.
Patients and methods
Study design
This was a phase III, randomized, open-label, parallel-
group, active-comparator, non-inferiority trial (EudraCT
number 2006-000644-13). Patients were enrolled in 15
centers in Italy coordinated by the Italian Trials in Medical
Oncology (I.T.M.O.) Group. This was an unsponsored,
investigator-initiated trial. Design and methodology of this
trial, with the exception of blinding, were similar to those
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Palonosetron is a second-generation 5-HT3-receptor
antagonist that has a greater binding affinity and a
prolonged half-life (∼40 h) compared with first-generation
agents [10]. In two randomized, double-blind, controlled,
phase III, non-inferiority trials involving patients receiving
MEC, single-dose palonosetron (0.25 mg intravenously)
produced a statistically significant increase in the complete
response (CR) rate compared with single-dose ondansetron or
dolasetronfor CINV duringthedelayedandoverall phases[11,of the two phase III registration studies that assessed the
efficacy of palonosetron alone in patients receiving MEC
[11, 12]. The institutional review board at each study site
approved the study protocol, and patients provided written
informed consent prior to participation.
Eligibility criteria
Patients eligible for the study were adults with a histolog-
ically or cytologically confirmed solid tumor receiving
chemotherapy for the first time with intravenous agents
classified as moderately emetogenic according to the
modified Hesketh chemotherapy classification given as
single doses on study day 1 [5]. Patients were required to
have acceptable hematologic, hepatic, and renal functions for
administration of chemotherapy, and an adequate Eastern
Cooperative Oncology Group (ECOG) performance status of
0, 1, or 2. Patients could not receive any drug with potential
anti-emetic efficacy other than the study drug given immedi-
ately before or during the study period, and could not receive
radiotherapywithin30 days beforechemotherapyinitiation or
during the study period. Patients were considered ineligible if
they had known central nervous system malignancy or
another organic cause for nausea or vomiting unrelated to
chemotherapyadministration.Nauseaorvomitingwithin24h
prior to initiation of chemotherapy also led to exclusion.
Patients were ineligible if they had active infection or were
unable to understand or cooperate with study procedures.
Pregnant or nursing women were ineligible.
Treatment plan and random assignment
Regardless of assignment to either study arm, all patients
received a single, fixed, intravenous dose of palonosetron
(0.25 mg) as a bolus over 30 s given 30 min before
chemotherapy initiation on day 1. Administration of
prophylactic dexamethasone (8 mg intravenously) within
15 min before chemotherapy initiation on day 1 was also
required. Patients were randomly assigned to one of two
delayed anti-emetic regimens: (1) no additional dexameth-
asone, or (2) dexamethasone (8 mg orally) on days 2 and 3.
After chemotherapy, rescue medication including dexa-
methasone and/or metoclopramide for the treatment of
nausea and vomiting was permitted on an as-needed basis.
Patients who met eligibility criteria were randomly assigned
to either treatment arm using an allocation schedule with a
block-size of four that had been generated before the trial
by an independent statistician.
Study endpoints and assessments
The primary efficacy endpoint of this study was CR
(defined as no emetic episodes, and no rescue medication
use) during the overall study period (days 1 through 5 after
chemotherapy initiation). Secondary endpoints were the
proportion of patients who achieved the following during
the overall, acute (0–24 h post-chemotherapy), and delayed
phase (24–120 h post-chemotherapy): CR (not including
overall phase), complete control (CC; defined as no emetic
episodes, no use of rescue medication, and no more than
mild nausea), no emesis (defined as no vomiting or
retching), no nausea, and no use of rescue medication. An
additional endpoint was severity of nausea that was
recorded on a four-point categorical Likert scale (0, none;
1, mild; 2, moderate; 3, severe), according to subjective
assessment by each patient.
Patients were instructed to record the relevant study
information in a diary provided by the investigators. To
assess efficacy, patients made daily entries in the diary for
5 days after chemotherapy initiation to record the number
and time of any emetic events in the previous 24 h, use of
rescue medication, and maximum nausea experienced in the
previous 24 h assessed by a Likert scale. Patients made
daily entries in the diary noting any adverse event or use of
concomitant medication. When patient returned to the clinic
for the second course of chemotherapy, the patient diary
was collected and reviewed to ensure adherence to the
required diary documentation and the prescribed study
medication at home. Adverse events judged by the
investigator to be possibly, probably, or definitely related
to the study treatment were regarded as a treatment-related
adverse event.
Statistical analysis
The intention-to-treat (ITT) cohort included patients who
received at least one dose of the study medication and MEC
chemotherapy. The per-protocol (PP) cohort included all
patients who received study medication and completed the
follow-up period (days 1–5 after chemotherapy initiation)
without any major protocol deviation. The safety cohort
included all patients who received at least one dose of the
study medication after randomization. The primary efficacy
hypothesis was that palonosetron plus a single-dose of
dexamethasone was non-inferior to palonosetron plus
dexamethasone for 3 days during the overall study period
(0–120 h post-chemotherapy) using a non-inferiority
margin of a 15% difference between groups in the
proportion of patients who had a CR. Considering previous
pivotal studies, the number of patients needed in the study
was estimated to be 330, who were distributed into two
groups (i.e., 165 patient/group) based on the assumption of
a CR rate of 70% in the two treatment groups and a
difference of −15% in the CR rate [11, 12]. To obtain 80%
statistical power with a one-sided α level of 0.025, a
sample size of 150 evaluable patients per group was
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group needed to be enrolled. To assess non-inferiority for
the primary endpoint of a CR rate at 120 h, the lower
boundary of the two-sided 95% confidence interval (CI) for
the difference (1-day dexamethasone minus 3-day dexa-
methasone) between the CR rates in the two treatment arms
was compared with the preset threshold.
The primary endpoint was analyzed for both the ITT
and PP cohort, and the results were interpreted in a
confirmatory manner to demonstrate the non-inferiority
hypothesis. The PP cohort was used for all secondary
efficacy analyses including the primary endpoint analyzed
in the multivariable context. The data analyses were
carried out by an independent statistician who was blinded
to study treatments.
Comparisons of CR during the acute phase (0–24 h), and
delayed phase (24–120 h) were preplanned secondary
analyses for either cohort. Consistency of treatment effect
(CR in the overall study period) across gender (female
versus male) and type of chemotherapy (anthracycline plus
cyclophosphamide (AC)-based versus non-AC-based) were
assessed by evaluating the first-order interactions between
treatment and either risk factor, included one by one into a
generalized linear model implemented with binomial
distribution and identity link function. This non-canonical
link function was adopted to estimate risk differences (RD)
instead of the usual odds ratios. RD allowed a straightfor-
ward comparison between the unadjusted (univariable
analysis) and adjusted (multivariable analysis) two-sided
95% CI of between-group difference in CR to anti-emetic
treatment for testing the non-inferiority.
A chi-square test was used to analyze the following: CC
rates; proportion of patients with no emetic episodes, no
nausea, or no rescue medication; and proportion of patients
with nausea (worst severity as assessed by the Likert scale).
Treatment-related adverse events occurring in at least 2% of
patients were summarized descriptively by treatment group.
The analyses of all secondary endpoints were evaluated
in an explorative or descriptive manner, and therefore no
adjustment for multiplicity was performed. All P values
were two-sided, and a P value <0.05 was considered
statistically significant. All statistical analyses were per-
formed using SAS software (version 9.1; SAS Institute,
Cary, NC).
Results
Patient characteristics
From October 13, 2006 to June 6, 2008, 334 patients were
randomized to receive palonosetron in combination with
dexamethasone as either a single dose or for 3 days. Two
patients did not receive study treatment (Fig. 1); thus, a
total of 332 patients were included in the ITT cohort for
efficacy analyses. Five patients were lost to follow-up (two
patients in the study arm and three in the reference arm) and
an additional three had a major protocol deviation (one
patient in the study arm and two in the reference arm).
Therefore, a total of 324 patients were evaluable for
efficacy analysis in the PP cohort.
Demographic and clinical characteristics for the ITT
cohort were similar between treatment groups (Table 1).
The majority of the study population (225 of 332 patients
(67.8%)) was less than 65 years of age, and most patients
(216 of 332 patients (65.1%)) were women. The majority of
patients were diagnosed with either breast (143 of 332
patients (43.1%)) or colorectal (121 of 332 patients
(36.4%)) cancers. Of the chemotherapeutic treatments
received on day 1 in the efficacy analyses, most patients
received either oxaliplatin-based regimens (119 of 332
patients (35.8%)) or AC-containing regimens (35.2% of the
study population).
Efficacy
The proportion of patients in either the ITT or PP cohort
achieving CR during the overall study period (0–120 h)
after MEC is presented in Table 2. Non-inferiority of the
1-day regimen was demonstrated, as the lower boundaries
of the 95% CI of the difference with the 3-day regimen
were greater than the preset threshold of −15% difference.
Fig. 1 Study flow chart. ITT intention-to-treat, PP per-protocol
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palonosetron plus 1-day dexamethasone was non-inferior to
the 3-day regimen. Secondary efficacy analyses are pre-
sented in Table 3. During the delayed phase, significantly
fewer patients receiving the 1-day dexamethasone regimen
required no rescue medication compared with those who
received the 3-day regimen. When the proportion of
patients with no emesis or nausea was assessed daily, there
were also no statistically significant differences between
groups at any time point after chemotherapy initiation (data
not shown).
Subset analyses of each treatment group by gender and
type of chemotherapy administered were done for CR
during the acute and delayed phases (Table 4). Lower rates
of CR were observed for palonosetron plus single-dose
dexamethasone compared with palonosetron plus 3-day
dexamethasone in women during the delayed phase (24–
120 h). CR rates in the subgroup of patients receiving non-
AC MEC regimens showed no difference between treat-
ment groups in the acute and delayed phases. Fewer
patients receiving AC-containing regimens achieved CR
in the 1-day regimen with respect to those in the 3-day
regimen during the delayed phase. It should be noted that
half of the female patients (1-day regimen, 49.5%; 3-day
regimen, 52%) in either arm received AC-containing
chemotherapy. There were no significant interactions
between treatment and either gender (P=0.512) or type of
chemotherapy (P=0.672) in the overall study period for the
primary endpoint of CR. On univariable analysis only
female gender (RD 14.7%; 95% CI, 4.7 to 24.7%; P=
0.004) and AC-containing chemotherapy (RD 12.8%; 95%
CI, 2.0 to 23.6%; P=0.020) were associated with worse
outcome in terms of overall CR to anti-emetic treatment.
Nevertheless such associations were no longer statistically
Variable Palo plus 1-day Dex
a (n=166) Palo plus 3-day Dex (n=166)
Age categories (n (%))
<65 years 114 (68.7) 111 (66.9)
≥65 years 52 (31.3) 55 (33.1)
Mean (±SD) 56.9 (±11.8) 57.2 (±11.3)
Body weight (kg)
Mean (±SD) 68.8 (±14.7) 66.6 (±12.6)
Height (cm)
Mean (±SD) 163.7 (±8.9) 163.1 (±7.8)
Gender (n (%))
Female 103 (62) 113 (68.1)
Male 63 (38) 53 (31.9)
ECOG score
b (n (%))
0 152 (91.6) 152 (91.6)
1 14 (8.4) 13 (7.8)
2 0 1 (0.6)
Tumor type (n (%))
Breast 65 (39.2) 78 (47)
Colorectal 65 (39.2) 56 (33.7)
Lung 15 (9.0) 13 (7.8)
Other 21 (12.6) 19 (11.5)
Alcohol consumption (n (%))
No 101 (60.8) 99 (59.6)
Everyday
c 65 (39.2) 67 (40.4)
Tumor stage (n (%))
Early 98 (59) 115 (69.3)
Metastatic 68 (41) 51 (30.7)
Chemotherapy (n (%))
AC-based
d 54 (32.5) 63 (38)
Oxaliplatin-based 64 (38.6) 55 (33.1)
Carboplatin-based 21 (12.7) 16 (9.6)
Irinotecan-based 14 (8.4) 15 (9.1)
Other 13 (7.8) 17 (10.2)
Table 1 Baseline demographic
and clinical characteristics in
the intention-to-treat cohort
aPalonosetron plus dexamethasone
bEastern Cooperative Oncology
Group
c1–2 glasses of wine
dAnthracycline plus
cyclophosphamide
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and multivariable analysis the lower boundaries of the 95%
CI of between-group difference were greater than the preset
threshold of −15% (univariable: RD −3.3%; 95% CI, −13.4
to 6.8%; P=0.520; multivariable: RD −4.4%; 95% CI,
−14.1 to 5.4%; P=0.381). Therefore, the non-inferiority
hypothesis of the 1-day regimen was proven also after
adjusting for the model covariates.
The severity of nausea was not significantly different
between groups for each study day or during the delayed
and overall phases. However, this was only an exploratory
analysis due to the unblinded design of the study. The
majority of nausea was mild in severity during the delayed
phase (1-day regimen, 33.7%; 3-day regimen 29.2%); very
few patients reported nausea of at least moderate severity
on any study day in the 1-day regimen (2.4% to 4.9% of
patients) or in the 3-day regimen (3.1% to 6.8% of
patients). In both groups, very few patients experienced
severe nausea within 24 h (0 of 163 patients in the 1-day
regimen and four of 161 patients (2.5%) in the 3-day
regimen). Only one patient receiving the 1-day regimen had
severe nausea 120 h after chemotherapy initiation.
Tolerability
A total of 332 patients were evaluable for safety. Overall,
159 patients (47.9%) reported one or more adverse events
(both related and unrelated to study treatment), 82 patients
(49.4%) in the 1-day regimen and 77 patients (46.4%) in
the 3-day regimen. There were no clinically relevant
differences between groups with respect to the overall
incidence of adverse events. The most common treatment-
related adverse events in either treatment group were
headache (1-day regimen, 19.9%; 3-day regimen, 13.9%)
followed by constipation (9.6% and 10.8%, respectively)
and fatigue (9.0% and 4.2%, respectively). No serious
adverse events occurred during the study.
Discussion
In the current phase III trial, the primary hypothesis of non-
inferiority of palonosetron plus single-dose dexamethasone
compared with 3-day dexamethasone regimen in the
prevention of CINV following a broad range of MEC
Table 2 Complete response (defined as no emetic episodes and no use of rescue medication) rates in the study cohorts
Complete responses
Palo plus 1-day Dex
a (n (%)) Palo plus 3-day Dex (n (%)) Difference between groups
b
(95% CI), %
P
c
ITT cohort
d, n=332 n=166 n=166
Acute phase (0–24 h) 147 (88.6) 140 (84.3) 4.2 (−3.1 to 11.6) 0.262
95% CI 82.7 to 92.9 77.9 to 89.5
Delayed phase (24–120 h) 114 (68.7) 129 (77.7) −9.0 (−18.5 to 0.4) 0.116
95% CI 61.0 to 75.6 70.6 to 83.8
Overall phase
e (0–120 h) 112 (67.5) 118 (71.1) −3.6 (−13.5 to 6.3) ND
95% CI 59.8 to 74.5 63.6 to 77.9
PP cohort
f, n=324 (n=163) (n=161)
Acute phase (0–24 h) 144 (88.3) 135 (83.9) 4.5 (−3 to 12) 0.242
95% CI 82.4 to 92.8 77.2 to 89.2
Delayed phase (24–120 h) 112 (68.7) 124 (77.0) −8.3 (−17.9 to 1.3) 0.093
95% CI 60.9 to 75.7 69.7 to 83.3
Overall phase
e (0–120 h) 109 (66.9) 113 (70.2) −3.3 (−13.4 to 6.8) ND
95% CI 59.1 to 74.0 62.5 to 77.1
ND not done
aPalonosetron plus dexamethasone
b1-day minus 3-day regimen with 95% confidence interval obtained using normal approximation of binomial data
cTwo-sided chi-square test (1-day vs. 3-day)
dIntention-to-treat
eNon-inferiority hypothesis in primary analysis was proven as the lower boundaries of the 95% CI of between-group difference were greater than the preset
threshold (−15%)
fPer-protocol cohort
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120 h post-chemotherapy).
In patients receiving MEC, current guidelines recom-
mend a combination of a 5-HT3-receptor antagonist and
dexamethasone before chemotherapy initiation, with either
agent given alone on days 2 and 3 [3]. However, the use of
dexamethasone in clinical practice remains limited because of
concernsaboutpotentialsideeffectsand/orotherfactors[5, 8].
Table 3 Secondary efficacy analyses in the per-protocol cohort
Variable Palo plus 1-day Dex
a (n=163), n (%) Palo plus 3-day Dex (n=161), n (%) Difference
b, 95% CI (%)
Complete control
c
Acute phase (0–24 h) 142 (87.1) 132 (82.0) 5.1 (−2.7 to 13)
Delayed phase (24–120 h) 108 (66.3) 122 (75.8) −9.5 (−19.3 to 0.3)
Overall phase (0–120 h) 105 (64.4) 109 (67.7) −3.3 (−13.6 to 7)
No emetic episodes
Acute phase (0–24 h) 153 (93.9) 148 (91.9) 1.9 (−3.7 to 7.5)
Delayed phase (24–120 h) 140 (85.9) 145 (90.1) −4.2 (−11.2 to 2.9)
Overall phase (0–120 h) 134 (82.2) 135 (83.9) −1.6 (−9.8 to 6.5)
No nausea
Acute phase (0–24 h) 128 (78.5) 117 (72.7) 5.9 (−3.5 to 15.2)
Delayed phase (24–120 h) 93 (57.1) 100 (62.1) −5.1 (−15.7 to 5.6)
Overall phase (0–120 h) 85 (52.1) 91 (56.5) −4.4 (−15.2 to 6.5)
No use of rescue medication
Acute phase (0–24 h) 148 (90.8) 144 (89.4) 1.4 (−5.1 to 7.9)
Delayed phase (24–120 h) 119 (73.0) 134 (83.2)* −10.2 (−19.2 to −1.3)
Overall phase (0–120 h) 116 (71.2) 129 (80.1) −9( −18.3 to 0.3)
*P=0.026 (two-sided Chi-square test (1-day vs. 3-day))
apalonosetron plus dexamethasone
b1-day minus 3-day regimen with 95% confidence interval obtained using normal approximation of binomial data
cNo emetic episodes, no use of rescue medication, and no more than mild nausea
Table 4 Subgroup analysis by gender and type of chemotherapy of the complete response (defined as no emetic episodes and no rescue
medication) rates in the per-protocol cohort
Complete responses
Palo plus 1-day Dex
a (n (%)) Palo plus 3-day Dex (n (%))
bDifference, 95% CI (%)
Acute phase (0–24 h) Gender
Women 88/101 (87.1) 85/109 (78) 9.1 (−1 to 19.3)
Men 54/62 (87.1) 47/52 (90.4) −3.3 (−14.9 to 8.3)
Chemotherapy
AC-based
c 44/52 (84.6) 45/61 (73.8) 10.8 (−3.9 to 25.6)
Non-AC-based 98/111 (88.3) 87/100 (87.0) 1.3 (−7.6 to 10.2)
Delayed phase (24–120 h) Gender
Women 62/101 (61.4) 81/109 (74.3)* −12.9 (−25.5 to −0.4)
Men 46/62 (74.2) 41/52 (78.8) −4.7 (−20.2 to 10.9)
Chemotherapy
AC-based
c 29/52 (55.8) 46/61 (75.4)** −19.6 (−36.9 to −2.3)
Non-AC-based 79/111 (71.2) 76/100 (76.0) −4.8 (−16.7 to 7)
*P=0.045 (two-sided chi-square test (1-day vs. 3-day)); **P=0.028
aPalonosetron plus dexamethasone
b1-day minus 3-day regimen with 95% confidence interval obtained using normal approximation of binomial data
cAnthracycline plus cyclophosphamide
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palonosetron has been recently reported to lead to receptor
alteration or internalization resulting in a extended inhi-
bition of receptor function [16]. Two phase III trials have
demonstrated that palonosetron alone is effective in
preventing both acute and delayed CINV following MEC
[11, 12].
Following the design and methodology of the pivotal
phase III trials, we have explored the hypothesis that
additional dexamethasone doses beyond day 1 of MEC
administration may not be necessary in patients receiving
palonosetron. In the current study, which included a
heterogeneous patient population receiving commonly
administered MEC regimens to reflect actual clinical
practice, CR rates were 89% in the 1-day regimen arm
versus 84% in the 3-day regimen arm during the acute
phase. Response rates were 68% versus 71%, respectively,
for complete protection against CINV during the overall
study period. However, analysis of the components of CR,
vomiting and use of rescue medication, showed that fewer
patients taking a single dexamethasone dose reported no
rescue medication use during the delayed phase. The added
benefit for this secondary endpoint in patients taking
additional dexamethasone doses is most likely related to
the characteristics of the study population. Women
accounted for the majority of patients in each treatment
group, and half of the female patients in either arm received
AC-containing chemotherapy. This may bias the anti-
emetic protection against delayed CINV in the patient
cohort receiving no additional dexamethasone less favor-
ably than cohort taking dexamethasone on days 2 and 3. A
subgroup analysis showed that the standard 3-day regimen
was better than the 1-day regimen for complete protection
against delayed CINV in women (61.4% versus 74.3%; P=
0.045). It is well known that women who receive AC-
containing chemotherapy have a particularly high risk of
developing CINV, but at the time the current trial was
planned, the AC-based regimens were considered as MEC
[17]. Within the AC subgroup, the standard regimen
appeared to be more efficacious in the delayed phase in
comparison with the 1-day regimen (CR, 55.8% versus
75.4%; P=0.028). A recently reported double-blind, phase
III trial evaluated the efficacy of palonosetron plus 1-
versus 3-day dexamethasone in chemotherapy-naïve female
breast cancer patients (n=300) receiving anthracycline and/
or cyclophosphamide-containing chemotherapy [18]. Non-
inferiority between the two treatments was demonstrated by
similar CR rates in the overall period (study primary
endpoint) but, interestingly, patients receiving the 3-day
dexamethasone regimen experienced on day 3 less emesis
than the group receiving a single dose of dexamethasone
(89% versus 97%, P=0.004). In the current study, on
univariable analysis female gender and AC-containing
chemotherapy were significantly associated with worse
outcome. Such associations were no longer statistically
significant in a multivariable analysis, but the trial was not
powered to enable careful assessment of whether there is
any difference in efficacy from gender and the type of
chemotherapy. In patients with breast cancer receiving AC-
containing chemotherapy, the MASCC/ESMO anti-emetic
guidelines, recently updated in 2010, recommend a 5-HT3-
receptor antagonist in combination with dexamethasone
and an neurokinin-1 receptor antagonist (aprepitant or
fosaprepitant) to prevent acute CINV, with aprepitant given
alone on days 2 and 3 for prevention of delayed symptoms
[19]. In a phase II trial evaluating the efficacy of palonosetron
plus 3-day dexamethasone and aprepitant in 58 patients
receiving MEC (including AC-containing chemotherapy in
41% of cases), 78% of patients achieved CR during the
delayed and overall phases [20]. More recently, results from a
phase II study that included 41 patients (40 were female)
receiving MEC (including AC-containing chemotherapy in
90% of cases) indicated that a single-day regimen of
palonosetron, dexamethasone and aprepitant is feasible and
effective for protection against acute and delayed vomiting
[21]. In the light of this, a single-day three-drug anti-emetic
regimen should be formally compared with the standard
multi-day regimen in female patients for the prevention of
CINV following AC-containing chemotherapy.
We acknowledge that as the present trial was unblinded
this could have potentially influenced the results. However,
the consistency of the efficacy results observed in the 1-day
regimen arm with those previously reported on palonosetron
supports the validity of the current study [13, 15, 22].
In conclusion, we provide evidence that the combination
of palonosetron and dexamethasone given on day 1 of
common MEC regimens is non-inferior to the same
regimen with dexamethasone also administered on days 2
and 3 for the complete protection against acute and delayed
CINV. It is important to remember that the current study
was not designed to address whether the 1-day regimen
should be pursued or not according to the type of MEC
chemotherapy. An unplanned subgroup analysis suggested
that the major benefit of the 1-day regimen occurs in
patients receiving non-AC-containing chemotherapy (65%
of the study population). Therefore, in patients receiving
MEC other than AC-based regimens, this dexamethasone
sparing regimen minimizes medication administration that
patients must remember at home and provides the potential
to improve both adherence with anti-emetic prophylaxis
and quality of life.
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